A Comparative Clinical Trial to Evaluate the effect of Triphaladi Guggulu vati and Varun Shigru vati in patient of garbhasya arbuda(rasouli)

A Comparative Clinical Trial To Evaluate The Effect Of Triphaladi Guggulu Vati And Varun Shigru Guggulu Vati in the management of Garbhashya Arbuda w.s.r to Uterine fibroid

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/03/032198

Enrollment

Registered

2021-03-22

Start date

Unknown

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N85- Other noninflammatory disorders ofuterus, except cervix

Interventions

Intervention1: Triphaladi guguulu vati: Dose - 500mg twice a day for three months. Control Intervention1: Varun shigru guggulu vati: Dose - 500 mg twice a day for three months.

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patient having symptoms of uterine fibroid. 2.Fibroid size less or equal to 5 cm as per usg report(single or multiple fibroid). 3.Patient willing to participate in this trial therapy.

Exclusion criteria

Exclusion criteria: 1.Patient below the age of 20 and above the age of 45 years. 2.Patient having fibroid size >5cm as per usg report. 3.Fibroid in pregnancy. 4.Fibroid with severe menstrual disturbance like metrorrhagia, menometrorrhagia, polymennorrhea etc. 5.Woman with Hb 6.Patient using IUCD or taking OC pills. 7.Patient suffering from any other organic pathology like ovarian tumor, tubo-ovarian mass, endometriosis, PID, malignancy etc. 8. Patient suffering from any systemic illness which may be deteriorate her general health like HTN, DM, TB, Cardiac disorder, Thyroid dysfunction etc.

Design outcomes

Primary

Measure	Time frame
1. To assess the effect of Triphaladi guggulu vati and varun shigru guggulu vati in the management of Garbhashaya arbud w.s.r. uterine fibroid. 2. To assess the trial drug on subjective parameters like menorrhagia, dysmenorrhea, dyspareunia, pain and heaviness in lower abdomen, backache, frequent urination, constipation and objective parameter are Hb%,TLC,DLC, ESR, Platelet count, CT,BT,USG(lower abdomen).Timepoint: Final assessment will be done after completion of trial of 4 month.	—

Measure

Time frame

1. To assess the effect of Triphaladi guggulu vati and varun shigru guggulu vati in the management of Garbhashaya arbud w.s.r. uterine fibroid. 2. To assess the trial drug on subjective parameters like menorrhagia, dysmenorrhea, dyspareunia, pain and heaviness in lower abdomen, backache, frequent urination, constipation and objective parameter are Hb%,TLC,DLC, ESR, Platelet count, CT,BT,USG(lower abdomen).Timepoint: Final assessment will be done after completion of trial of 4 month.

—

Secondary

Measure	Time frame
To assess the trial drug on subjective parameters like menorrhagia, dysmenorrhea, dyspareunia, pain and heaviness in lower abdomen, backache, frequent urination, constipation.Timepoint: Follow up - every month during trial.	—

Countries

India

Contacts

Public ContactDrVandana singh patel

State Ayurvedic Collage and Hospital Lucknow lucknow

drshikhasharma1982@gmail.com8743976379

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026